NasdaqCM:TGTXBiotechs
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Efficacy Data In Relapsing Multiple Sclerosis
Why the latest BRIUMVI data matters for TG Therapeutics investors
TG Therapeutics (TGTX) is back in focus after publishing a post hoc pooled analysis from its Phase 3 ULTIMATE I and II trials, showing BRIUMVI cut relapse rates and MRI activity in highly active relapsing multiple sclerosis.
See our latest analysis for TG Therapeutics.
At a share price of $27.96, TG Therapeutics has a 1-day share price return of 3.79%. However, the 90-day share price return of a 10.81% decline and the 1-year...